Alectinib regulatory update

Chugai submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for alectinib to treat unresectable, recurrent or advanced anaplastic lymphoma kinase (ALK) fusion gene-positive non-sm...